Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers
NCT02668367Phase 1Completed
- Sponsor
- Aviragen Therapeutics
- Start
- Nov 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing BTA-C585 with Placebo (2 arms). Primary endpoints: Area under the plasma concentration-time curve from time 0 to 24 hours and Number of adverse events. Started Nov 2015; status: completed.
02
Drugs
enzaplatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02668367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02668367.